Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brachytherapy-related dysuria.

Gregory S Merrick1, Wayne M Butler, Kent E Wallner

  • 1Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV 26003-6300, USA. SchifflerCancerCenter@wheelinghospital.com

BJU International
|February 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the Beam: Redefining Survivorship in Prostate Cancer.

International journal of radiation oncology, biology, physics·2025
Same author

Prospective Evaluation of Supplemental External Beam Radiation Therapy With Palladium-103 Prostate Brachytherapy: Long-Term Results of the 44/20/0 Trials.

Practical radiation oncology·2024
Same author

External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.

International journal of radiation oncology, biology, physics·2022
Same author

ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer.

American journal of clinical oncology·2022
Same author

The impact of age on prostate cancer progression and quality of life in active surveillance patients.

BJUI compass·2022
Same author

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.

JAMA oncology·2022
Same journal

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

BJU international·2026
Same journal

Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.

BJU international·2026
Same journal

A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.

BJU international·2026
Same journal

Ablative radiotherapy in castration-resistant prostate cancer.

BJU international·2026
Same journal

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.

BJU international·2026
Same journal

Venous thromboembolism after penile cancer surgery: a UK PeCaN study.

BJU international·2026
See all related articles

Dysuria is common after prostate brachytherapy but usually mild. Prophylactic alpha-blockers reduce initial severity but don't speed resolution. Maximum IPSS post-implant best predicts dysuria resolution.

Area of Science:

  • Urology
  • Radiation Oncology
  • Oncology

Background:

  • Permanent prostate brachytherapy is a common treatment for localized prostate cancer.
  • Urinary side effects, particularly dysuria, are frequent concerns following the procedure.

Purpose of the Study:

  • To determine the incidence and time course of dysuria after permanent prostate brachytherapy.
  • To identify factors that predict the development and resolution of brachytherapy-related dysuria.

Main Methods:

  • A prospective study of 130 patients undergoing prostate brachytherapy (103Pd or 125I) with urethral-sparing techniques.
  • Patients received either prophylactic alpha-blockers or placebo; dysuria was assessed on a 0-10 scale at multiple time points.
  • Clinical, treatment, and dosimetric variables were analyzed for predictive value.

Related Experiment Videos

Main Results:

  • Dysuria occurred in up to 85% of patients at 1 month post-brachytherapy, with gradual resolution.
  • Prophylactic tamsulosin significantly reduced initial dysuria severity but did not alter resolution time.
  • Higher post-treatment International Prostate Symptom Score (IPSS) and isotope type (103Pd) were associated with faster dysuria resolution.

Conclusions:

  • Dysuria is a common but generally mild side effect of prostate brachytherapy.
  • While prophylactic alpha-blockers can mitigate initial severity, the maximum IPSS post-implant is the strongest predictor of dysuria resolution.